157 related articles for article (PubMed ID: 24191959)
1. Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.
Zhao S; Kuge Y; Zhao Y; Takeuchi S; Hirata K; Takei T; Shiga T; Dosaka-Akita H; Tamaki N
BMC Cancer; 2013 Nov; 13():525. PubMed ID: 24191959
[TBL] [Abstract][Full Text] [Related]
2. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Bzorek M; Jensen PB; Højgaard L; Sehested M; Kjær A
PLoS One; 2013; 8(1):e53410. PubMed ID: 23308217
[TBL] [Abstract][Full Text] [Related]
3. Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
Zhou LN; Wu N; Liang Y; Gao K; Li XY; Zhang LF
World J Surg Oncol; 2015 Mar; 13():111. PubMed ID: 25888731
[TBL] [Abstract][Full Text] [Related]
4. Sex as a Biologic Variable in Preclinical Imaging Research: Initial Observations with
Chan SR; Salem K; Jeffery J; Powers GL; Yan Y; Shoghi KI; Mahajan AM; Fowler AM
J Nucl Med; 2018 May; 59(5):833-838. PubMed ID: 29217733
[TBL] [Abstract][Full Text] [Related]
5. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
Pan Y; Xu Y; Feng S; Luo S; Zheng R; Yang J; Wang L; Zhong L; Yang HY; Wang BL; Yu Y; Liu J; Cao Z; Wang X; Ji P; Wang Z; Chen X; Zhang S; Wei YQ; Yang SY
Mol Cancer Ther; 2012 Apr; 11(4):952-62. PubMed ID: 22319204
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
7. [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.
Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
BMC Cancer; 2013 Apr; 13():168. PubMed ID: 23548101
[TBL] [Abstract][Full Text] [Related]
8. Effect of gemcitabine on the uptake of (18)F-fluorodeoxyglucose and (18)F-fluorothymidine in lung adenocarcinoma A549 cells and the animal tumor model.
Zhang B; Deng SM; Guo LC; Dong JJ; Zhu YB; Gao Y; Wang ZX; Cho WC
J Cancer Res Ther; 2016; 12(1):271-6. PubMed ID: 27072250
[TBL] [Abstract][Full Text] [Related]
9. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
10. Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT.
Fatema CN; Zhao S; Zhao Y; Yu W; Nishijima K; Yasuda K; Kitagawa Y; Tamaki N; Kuge Y
BMC Cancer; 2014 Sep; 14():692. PubMed ID: 25245041
[TBL] [Abstract][Full Text] [Related]
11. [18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.
Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
PLoS One; 2012; 7(11):e50618. PubMed ID: 23226334
[TBL] [Abstract][Full Text] [Related]
12. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model.
Gong J; Yang DJ; Kohanim S; Angelo LS; Kurzrock R
Cancer Biol Ther; 2009 Dec; 8(23):2239-47. PubMed ID: 19823028
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice.
Sugiyama M; Sakahara H; Sato K; Harada N; Fukumoto D; Kakiuchi T; Hirano T; Kohno E; Tsukada H
J Nucl Med; 2004 Oct; 45(10):1754-8. PubMed ID: 15471845
[TBL] [Abstract][Full Text] [Related]
15. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
[TBL] [Abstract][Full Text] [Related]
16. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
[TBL] [Abstract][Full Text] [Related]
17. A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer.
Mansure JJ; Nassim R; Chevalier S; Szymanski K; Rocha J; Aldousari S; Kassouf W
PLoS One; 2013; 8(2):e55997. PubMed ID: 23409107
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.
Sunaga N; Oriuchi N; Kaira K; Yanagitani N; Tomizawa Y; Hisada T; Ishizuka T; Endo K; Mori M
Lung Cancer; 2008 Feb; 59(2):203-10. PubMed ID: 17913282
[TBL] [Abstract][Full Text] [Related]
19. Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model.
Hayakawa H; Ichihara E; Ohashi K; Ninomiya T; Yasugi M; Takata S; Sakai K; Matsumoto K; Takigawa N; Tanimoto M; Kiura K
Cancer Sci; 2013 Nov; 104(11):1440-6. PubMed ID: 24033722
[TBL] [Abstract][Full Text] [Related]
20. Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
Myers MV; Manning HC; Coffey RJ; Liebler DC
Mol Cell Proteomics; 2012 Feb; 11(2):M111.015222. PubMed ID: 22147731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]